Chimerix, Inc. (NASDAQ:CMRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

A number of other brokerages have also recently commented on CMRX. Cowen and Company restated a “hold” rating and set a $6.00 target price on shares of Chimerix in a report on Friday, April 28th. FBR & Co restated a “hold” rating and set a $7.00 target price on shares of Chimerix in a report on Monday, May 1st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Chimerix has a consensus rating of “Hold” and a consensus target price of $7.55.

Chimerix (NASDAQ CMRX) traded down 0.77% on Monday, hitting $5.18. 164,315 shares of the company’s stock were exchanged. Chimerix has a 52-week low of $3.66 and a 52-week high of $6.64. The stock’s market cap is $241.65 million. The firm has a 50 day moving average price of $4.93 and a 200-day moving average price of $5.38.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.01. Chimerix had a negative net margin of 1,221.34% and a negative return on equity of 24.07%. The business had revenue of $1.08 million for the quarter, compared to the consensus estimate of $1.56 million. Analysts predict that Chimerix will post ($1.73) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Upgrades Chimerix, Inc. (CMRX) to “Hold”” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/17/zacks-investment-research-upgrades-chimerix-inc-cmrx-to-hold.html.

Hedge funds have recently made changes to their positions in the stock. Eagle Asset Management boosted its stake in shares of Chimerix by 66.4% in the third quarter. Eagle Asset Management now owns 2,374,366 shares of the biopharmaceutical company’s stock worth $90,700,000 after buying an additional 947,047 shares during the period. DIAM Co. Ltd. boosted its stake in shares of Chimerix by 1.0% in the fourth quarter. DIAM Co. Ltd. now owns 213,406 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 2,099 shares during the period. Rhenman & Partners Asset Management boosted its stake in shares of Chimerix by 357.1% in the fourth quarter. Rhenman & Partners Asset Management now owns 256,000 shares of the biopharmaceutical company’s stock worth $2,291,000 after buying an additional 200,000 shares during the period. BlackRock Group LTD boosted its stake in shares of Chimerix by 30.2% in the first quarter. BlackRock Group LTD now owns 23,048 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 5,344 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Chimerix by 21.6% in the first quarter. TIAA CREF Investment Management LLC now owns 188,813 shares of the biopharmaceutical company’s stock worth $965,000 after buying an additional 33,495 shares during the period. Hedge funds and other institutional investors own 66.76% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.